Novartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal
arcticnovartis
Ad-hoc-Mitteilung gemäss Art. 53 KR
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
arcticnovartis
Ad hoc announcement pursuant to Art. 53 LR
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
arcticnovartis
Ad hoc announcement pursuant to Art. 53 LR
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
arcticnovartis
- After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of Novartis
- Karen Hale to drive the next phase of enterprise alignment for our Legal and ERC functions
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
arcticnovartis
Ad hoc announcement pursuant to Art. 53 LR
ADDRESS
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
CALL US
+263 (242) 741 308
+263 (242) 741 309
Mon-Fri: 8am – 5pm
